Programme

ESE Clinical Update on Prolactinomas
Provisional Programme

Please note - the topics and speakers may change between now and the start of the meeting


Wednesday 29 June: Diagnosis and burden
16:00 - 18:00 CEST

Chairs: Niki Karavitaki (UK) & Gerald Raverot (France)

Hyperprolactinaemia and diagnostic pitfalls
Dominique Maiter (Belgium)

Young-onset prolactinomas - how to apply genetics in prolactinomas
Albert Beckers (Belgium)

Should metabolic aspects influence treatment decisions in prolactinomas
Emanuel Christ (Switzerland) 

 

Clinical cases submitted and presented by attendees:

A young woman with cystic PRL-GH secreting macroadenoma harboring an AIP mutation
Arianna Cremaschi (Italy) 

Unprovoked seizure leading to the diagnosis of invasive macroprolactinoma
Elaine Soong (UK)

Giant prolactinoma in a young male patient complicated by multiple endocrine neoplasia type 1
Burçin Gönül İremli (Turkey)

 

 

Thursday 30 June: Management
16:00 - 18:00 CEST

Chairs: Monica Gadelha (Brazil) and Cristina Capatina (Romania)

Practical tips on management of prolactinomas
Mark Molitch (USA)

Age tailored prolactinoma management
Yona Greenman (Israel)

Fertility and pregnancy
Andrea Glezer (Brazil)

 

Clinical cases submitted and presented by attendees

Prolactinoma: when surgery is the answer
Maria Inês Alexandre (Portugal)

Discordant response in macroprolactinoma – a clinical case
Henrique Carmona Alexandrino (Portugal)

Giant prolactinoma: when should we expect control of prolactin levels?
Marta García Goñi (Spain)

 

 

Friday 1 July: Challenges and Future landscape
16:00 - 18:00 CEST

Chairs: Justo Castano (Spain) and Jurgen Honegger (Germany)

Any drug beyond dopamine agonists?
Renata Auriemma (Italy) 

Risks of treatments (surgery, medical and therapy)
Philippe Chanson (France)

Mutations of SF3B1 in prolactinomas and abnormal splicing in pituitary tumors: Any future therapeutic prospect? 
Justo Castano (Spain) 

 

Clinical cases submitted and presented by attendees

Persistent hyperprolactinemia on high dose DA therapy
Liva Steina (Latvia) 

A fatal case of aggressive prolactinoma
Giada Cosentino (Italy) 

Cerebrospinal fluid leak after dopamine agonist therapy in a patient with a giant prolactinoma
Annalisa Montebello (UK)

 

CME

The European Society of Endocrinology Clinical Update on prolactinomas, Bristol, United Kingdom, 29/06/2022-01/07/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 6 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.